{
  "trial_id": "NCT02390869",
  "overall_assessment": "likely_ineligible",
  "inclusion": [
    {
      "criterion": "Age >18 years.",
      "label": "met"
    },
    {
      "criterion": "First or second relapse or progression following R-chemotherapy (Rituximab maintenance and IF radiotherapy are not considered treatment lines).",
      "label": "not_met"
    },
    {
      "criterion": "Previous treatment with Bendamustine can be considered eligible if relapse occurred after \u2265 24 months.",
      "label": "unknown"
    }
  ],
  "exclusion": [
    {
      "criterion": "Any lymphoma subtype other than FL including transformed FL",
      "label": "triggers"
    },
    {
      "criterion": "Radiotherapy within 3 months prior to study entry",
      "label": "triggers"
    }
  ],
  "notes": "Patient has Burkitt's Lymphoma, which is a different subtype than Follicular Lymphoma. They have also received radiotherapy recently.",
  "_meta": {
    "topic_id": "4",
    "trial_id": "NCT02390869",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}